June 27, 2024 – BD introduced the industrial launch of a brand new single-cell analysis software to assist scientists higher perceive how the molecular equipment in a cell features and the way it regulates modifications in a cell that may result in most cancers and different illnesses. Researchers around the globe are at present utilizing modern approaches to review a number of features of well being and illness on the single-cell stage. Within the ever-evolving area of organic analysis, the lately launched BD Rhapsody™ Single Cell ATAC-Seq (Assay for Transposase-Accessible Chromatin Utilizing Subsequent-Technology Sequencing) Assay allows scientists to carry out single-cell evaluation of the epigenome – the set of chemical marks, or epigenetic modifications, on the DNA in a single cell that comprise essential clues about mechanisms of illness.

Including an epigenomic layer view will play an important position in serving to researchers observe and perceive how environmental elements affect DNA and related cell operate. By buying such information about DNA, scientists can deepen their understanding of illness development and apply these classes to develop efficient therapies.

The BD Rhapsody™ ATAC-Seq Assay, BD Rhapsody™ TCR/BCR Subsequent Multiomic Assay and BD Rhapsody™ Intracellular CITE-seq Assay shall be commercially obtainable worldwide starting in June 2024 and are designed to be used on the BD Rhapsody™ Single-Cell Evaluation System, a mushy, microwell-based instrument for conducting single cell analysis. The BD single-cell multiomics portfolio is out there for buy from BD representatives or in some areas by way of our e-commerce portal. Extra info is out there at bdbiosciences.com or by way of BD gross sales representatives.

Discover out extra